JOP20170134A1 - مركبات بينزيميدازول مستبدلة جديدة، عمليات لتحضيرها، مستحضرات صيدلية تشملها واستخدامها لتحضير الأدوية - Google Patents

مركبات بينزيميدازول مستبدلة جديدة، عمليات لتحضيرها، مستحضرات صيدلية تشملها واستخدامها لتحضير الأدوية

Info

Publication number
JOP20170134A1
JOP20170134A1 JOJO/P/2017/0134A JOP20170134A JOP20170134A1 JO P20170134 A1 JOP20170134 A1 JO P20170134A1 JO P20170134 A JOP20170134 A JO P20170134A JO P20170134 A1 JOP20170134 A1 JO P20170134A1
Authority
JO
Jordan
Prior art keywords
preparation
processes
endometriosis
prophylaxis
treatment
Prior art date
Application number
JOJO/P/2017/0134A
Other languages
English (en)
Inventor
Nubbemeyer Reinhard
Ring Sven
Gunther Judith
Schmidt Nicole
Bothe Ulrich
Bomer Ulf
ANDRES Dorothee
Siebeneicher Holger
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of JOP20170134A1 publication Critical patent/JOP20170134A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

يتعلق هذا الطلب بمركبات benzimidazole جديدة مستبدلة، و عمليات لتحضيرها و استخدامها منفردة أو في توليفة ، لعلاج و / أو الوقاية من الأمراض، واستخدامها لإنتاج الأدوية لعلاج و / أو الوقاية من الأمراض، ولا سيما لعلاج و / أو الوقاية من الانتباذ البطاني الرحمي والألم المصاحب للانتباذ البطاني الرحمي و الأعراض الأخرى المرتبطة بالانتباذ البطاني الرحمي مثل عسر الطمث، عسر الجماع، عسر البول و عسر التغوط، و من الليفومة والتهاب المفاصل الروماتويدي و الالتهاب المفاصل الفقارية (على وجه الخصوص الالتهاب الفقاري المفصلي الصدفي و مرض بيخترف)، و الذئبة الحمامية والتصلب المتعدد، و الضمور البقعي، COPD، النقرس، اضطرابات الكبد الدهنية، و مقاومة الإنسولين واضطرابات الكلى، والاضطرابات الورمية والصدفية.
JOJO/P/2017/0134A 2016-05-31 2017-05-30 مركبات بينزيميدازول مستبدلة جديدة، عمليات لتحضيرها، مستحضرات صيدلية تشملها واستخدامها لتحضير الأدوية JOP20170134A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16172162 2016-05-31

Publications (1)

Publication Number Publication Date
JOP20170134A1 true JOP20170134A1 (ar) 2017-11-30

Family

ID=56096532

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2017/0134A JOP20170134A1 (ar) 2016-05-31 2017-05-30 مركبات بينزيميدازول مستبدلة جديدة، عمليات لتحضيرها، مستحضرات صيدلية تشملها واستخدامها لتحضير الأدوية

Country Status (5)

Country Link
AR (1) AR108642A1 (ar)
JO (1) JOP20170134A1 (ar)
TW (1) TW201803866A (ar)
UY (1) UY37267A (ar)
WO (1) WO2017207340A1 (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021222366A1 (en) * 2020-04-28 2021-11-04 Kymera Therapeutics, Inc. Irak inhibitors and uses thereof
WO2022156788A1 (zh) * 2021-01-22 2022-07-28 武汉人福创新药物研发中心有限公司 苯并咪唑化合物及其用途
CN113402499B (zh) 2021-06-21 2022-05-13 上海勋和医药科技有限公司 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH23995A (en) * 1984-01-09 1990-02-09 Janssen Pharmaceutica Nv 4((bicycle heterocyclyl)-methyl and hetero)piperidines
GB9306578D0 (en) 1993-03-30 1993-05-26 Merck Sharp & Dohme Therapeutic agents
EP1255750A1 (en) 2000-02-01 2002-11-13 Millenium Pharmaceuticals, Inc. INDOLE AND BENZIMIDAZOLE INHIBITORS OF FACTOR Xa
ES2367422T3 (es) 2001-10-09 2011-11-03 Amgen Inc. Derivados de imidazol como agentes antiinflamatorios.
IL164263A0 (en) 2002-04-12 2005-12-18 Pfizer Use of ep4 receptor ligands on the treatment of il-6 involved diseases
WO2004011440A1 (ja) * 2002-07-30 2004-02-05 Banyu Pharmaceutical Co., Ltd. ベンズイミダゾール誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤
ATE450533T1 (de) 2003-02-14 2009-12-15 Glaxo Group Ltd Carboxamidderivate
WO2005082866A2 (en) 2004-02-20 2005-09-09 Pfizer Limited Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
JP2008523046A (ja) 2004-12-08 2008-07-03 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー メチレン誘導体
US8247556B2 (en) 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
US7745477B2 (en) 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
CA2683785A1 (en) 2007-04-13 2008-10-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20100093747A1 (en) 2008-10-10 2010-04-15 Erica Brook Goodhew Method of inducing negative chemotaxis
US20140113898A1 (en) 2010-11-08 2014-04-24 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
WO2012107475A1 (en) 2011-02-10 2012-08-16 Syngenta Participations Ag Microbiocidal pyrazole derivatives
CN103443105A (zh) 2011-02-18 2013-12-11 沃泰克斯药物股份有限公司 作为离子通道调节剂的苯并二氢吡喃-螺环哌啶酰胺
WO2013042137A1 (en) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
CA2874303C (en) 2012-06-11 2020-10-13 Ucb Biopharma Sprl Tnf -alpha modulating benz imidazoles
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途

Also Published As

Publication number Publication date
TW201803866A (zh) 2018-02-01
UY37267A (es) 2018-01-02
AR108642A1 (es) 2018-09-12
WO2017207340A1 (de) 2017-12-07

Similar Documents

Publication Publication Date Title
JO3705B1 (ar) إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
MX381180B (es) Compuestos aminopirazina con propiedades antagonistas a2a.
SA518391624B1 (ar) Ror- منظمات جاما
JOP20220020B1 (ar) مثبطات kars تعتمد على akr1c3 ثلاثية الحلقة
MX2019010907A (es) Agonistas del receptor x farnesoide, y usos de los mismos.
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
JOP20200231B1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MX2018010032A (es) Formulaciones de antagonista de il-6 y sus usos.
HK1251481A1 (zh) 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法
PH12018502278A1 (en) Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
MX391392B (es) ANILLOS 5-5 FUSIONADOS COMO INHIBIDORES C5a.
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201790949A1 (ru) Замещенные 2,4-диаминохинолины в качестве новых противораковых средств
CY1124115T1 (el) Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες
BR112018069930A2 (pt) agonistas de ppar, compostos, composições farmacêuticas, e métodos de uso dos mesmos
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
WO2022093552A8 (en) Rev-erb agonists
UY37267A (es) Nuevos benzimidazoles sustituidos, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
EA201890789A1 (ru) Содержащая цинеол композиция для лечения заболеваний носа
AU2015328044A8 (en) Pharmaceutical composition comprising Aspirin, Metformin, and Serotonin with non-ionic surfactant
TH159903A (th) สูตรผสมแอนติบอดี il-17
TH182343B (th) องค์ประกอบทางเภสัชกรรมที่เสถียรซึ่งต้านวัณโรคในรูปของยาเม็ดแบนชนิดที่แตกตัว อย่างรวดเร็วซึ่งประกอบรวมด้วยแกรนูลของไอโซไนอาซิดและแกรนูลของ ไรฟาเพนทีน และกระบวนการเตรียมของมัน